Zimmer Biomet Holdings Inc (NYSE:ZBH) Director Betsy J. Bernard acquired 4,250 shares of the stock in a transaction on Wednesday, February 6th. The stock was bought at an average cost of $117.41 per share, for a total transaction of $498,992.50. Following the transaction, the director now owns 2,000 shares of the company’s stock, valued at approximately $234,820. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
NYSE ZBH opened at $120.58 on Friday. Zimmer Biomet Holdings Inc has a 12-month low of $96.99 and a 12-month high of $134.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.91 and a current ratio of 1.85. The company has a market capitalization of $24.11 billion, a PE ratio of 15.78, a price-to-earnings-growth ratio of 2.12 and a beta of 1.16.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Friday, February 1st. The medical equipment provider reported $2.18 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.18. Zimmer Biomet had a negative net margin of 4.78% and a positive return on equity of 13.17%. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the previous year, the firm posted $2.10 earnings per share. The company’s quarterly revenue was up .1% compared to the same quarter last year. Research analysts predict that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.
Several analysts have commented on the stock. TheStreet lowered shares of Zimmer Biomet from a “b-” rating to a “c” rating in a research report on Friday, February 1st. Barclays set a $113.00 price objective on shares of Zimmer Biomet and gave the stock a “sell” rating in a research report on Tuesday. Zacks Investment Research raised shares of Zimmer Biomet from a “sell” rating to a “hold” rating in a research report on Saturday, January 12th. Oppenheimer reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Saturday, February 2nd. Finally, Cantor Fitzgerald set a $135.00 price objective on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Friday, January 25th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $127.52.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Schroder Investment Management Group increased its holdings in Zimmer Biomet by 71.5% during the 2nd quarter. Schroder Investment Management Group now owns 64,996 shares of the medical equipment provider’s stock worth $7,233,000 after acquiring an additional 27,096 shares during the period. Atria Investments LLC bought a new stake in Zimmer Biomet during the 3rd quarter worth approximately $760,000. Bremer Trust National Association increased its holdings in Zimmer Biomet by 37.6% during the 3rd quarter. Bremer Trust National Association now owns 17,963 shares of the medical equipment provider’s stock worth $2,362,000 after acquiring an additional 4,910 shares during the period. Boltwood Capital Management increased its holdings in Zimmer Biomet by 5.7% during the 3rd quarter. Boltwood Capital Management now owns 7,788 shares of the medical equipment provider’s stock worth $1,023,000 after acquiring an additional 420 shares during the period. Finally, DNB Asset Management AS increased its holdings in Zimmer Biomet by 7.6% during the 3rd quarter. DNB Asset Management AS now owns 26,688 shares of the medical equipment provider’s stock worth $3,509,000 after acquiring an additional 1,880 shares during the period. 87.82% of the stock is currently owned by institutional investors.
WARNING: This piece of content was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2019/02/09/zimmer-biomet-holdings-inc-zbh-director-betsy-j-bernard-acquires-4250-shares.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Recommended Story: Bull Market
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.